Neuromuscular Blocking Agents, Neuromuscular Monitoring
Conditions
Brief summary
Neuromuscular blocking agents (NMBA) are commonly used in clinical practice during general anesthesia to facilitate induction, intubation and surgery. Some studies have shown that their use can be deleterious if not codified. Recent recommendations concerning their use and antagonization were published in 2023. Research hypothesis: Using a single-center, retrospective practice study, we aim to analyze whether the 2023 ASA and ESAIC recommendations are being implemented regarding the use of neuromuscular blocking agents.
Interventions
Administration of any neuromuscular blocking agent for surgery under general anesthesia
Sponsors
Erasme University Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
\- All patients undergoing surgery with use of neuromuscular blocking agents at our institution
Exclusion criteria
\- Incomplete electronic anesthesia record
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adherence to ASA and ESAIC guidelines for the use and monitoring of neuromuscular bocking agents (%) | 10 hours | Train of four (TOF) ratio and TOF-count, as well as post-tetanic count (PTC) will be extracted from the electronic anesthesia record together with the type, dosage and timing of neuromuscular blocking agents. At intubation, antagonisation and extubation, the use of monitoring, the correct dose for antagonising agents (neostigmine or sugammadex) will be recorded. Concordance with current guidelines from ASA (American society of anaesthesiologists) and ESAIC (European society of anaesthesia and intensive care) will be analysed with a Chi-square test (observed versus expected). The % of adherence to the guidelines will be reported. |
Countries
Belgium
Contacts
Primary ContactDenis Schmartz, MD
Backup ContactAndréa Gardon, MD
Outcome results
None listed